Exclusive: Chinese Oncology Big Data Firm LinkDoc Completes Series B Funding Round

VCBeat has exclusively learned that LinkDoc, the low-profile and somewhat enigmatic Chinese medical big data company focusing on the oncology field, also known as LinkDoc Technology Limited, has long completed its Series B financing round, with the transaction closed.

It is understood that this round of financing was jointly completed by Ally Bridge Group, a fund focused on cross-border healthcare investments, together with other leading international and domestic funds.

Cancer has long been the leading disease threatening public health in China. According to projections by the World Cancer Association, new cancer cases in China are expected to reach 4 million in 2020, with deaths reaching 3.5 million. Estimates from relevant national authorities indicate that annual total expenditures on cancer treatment in China have already reached hundreds of billions of RMB and will continue to rise as the number of new cases increases.

Cancer care has long been one of the most complex and challenging fields in medicine, heavily reliant on scientific research and big data. LinkDoc Technology aims to systematically collect clinical and post-diagnosis follow-up data from China’s healthcare system, then organize and aggregate these data before feeding them back to physicians. This approach is designed to assist doctors in formulating better treatment plans and to advance precision medicine in oncology. Additionally, such data can help more pharmaceutical companies accelerate the research and development, regulatory approval, and marketing of new drugs.

This investment in LinkDoc Technology marks another strategic move by Ally Bridge Group in the sector, following its December 2015 investment in AltheaDx, a leading U.S. company specializing in pharmacogenomic testing and analytical technologies. This further expands and strengthens Ally Bridge Group’s global footprint, particularly in the field of precision data-driven healthcare in China and the United States.

Frank Yu, Founder of Ally Bridge Group, stated, “Precision medicine based on big data from internet healthcare has become an irreversible global trend in the medical industry. This investment in LinkDoc Technology represents a significant component of Ally Bridge Group’s strategic layout in global precision digital healthcare and underscores our proactive deployment at the intersection of healthcare and the internet. Ally Bridge Group has invested in more than ten leading companies developing novel cancer therapeutics across the United States, Europe, and China. LinkDoc Technology’s focus on oncology aligns closely with Ally Bridge Group’s carefully crafted global strategy in the cancer field. Leveraging our professional expertise in the global healthcare industry, Ally Bridge Group will help LinkDoc Technology rapidly become a benchmark for precision digital healthcare in China.”

About LinkCare

Based in Beijing, LinkDoc Technology is a medical big data company dedicated to the field of oncology. The company has established partnerships with more than 200 of the leading cancer hospitals across China. It has collected, organized, and analyzed over 400,000 patient cases, covering all tumor types and disciplines, with its technological reserves and business scale ranking among the industry leaders.

About Ally Bridge Group

Founded by Frank Yu, Ally Bridge Group is a global healthcare investment platform. Its leadership team includes Mr. Yu Fan, Dr. Li Bin (a renowned former Chief Healthcare Industry Analyst at Morgan Stanley), and other world-class healthcare experts. Ally Bridge Group and its affiliates manage over $1 billion in assets, with portfolio companies spanning China, the United States, and Europe. The firm has invested in numerous cutting-edge global medical device and biopharmaceutical technologies and possesses extensive experience in facilitating strategic partnerships between leading international healthcare corporations and emerging technology companies.

In 2015, Ally Bridge Group joined forces with the founder of WuXi AppTec to initiate, lead, and successfully complete the $3.3 billion privatization transaction of WuXi AppTec (NYSE: WX), a globally leading one-stop life science services platform. This landmark deal remains the largest private equity transaction in China’s healthcare industry to date.